Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible for appetite and eating behaviors, almost nothing is known about how these drugs affect the brain in youth who are treated for obesity, or how these drugs affect the brain of youth differently from adults. The goal of the current study is to compare youth and adults with obesity who are treated a GLP-1RA and measure potential difference in GLP-1RA associated change in brain function, appetite, and eating behaviors.

Start Date01 May 2026

Sponsor / Collaborator

University of Colorado Denver

[+1]

NCT06913023

/ Not yet recruitingPhase 2/3IIT

Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of placebo and semaglutide therapy in 74 KTR at risk of post-transplant diabetes mellitus (PTDM).

Start Date05 Jan 2026

Sponsor / Collaborator

University Health Network

NCT06977438

/ Not yet recruitingPhase 4IIT

Promoting Healthy Children and Youth

The rapid emergence of new and highly effective obesity medications has turned the field of pediatric weight management on its head. Adolescents living with obesity, their caregivers, healthcare providers, healthcare systems, policymakers, and payors are now wondering what role health behavior and lifestyle treatment (HBLT) has in terms of body mass index (BMI) reduction, improvements in quality of life and cardiometabolic health, and mitigating nutritional concerns when medications are used. Is intensive (26+ hours) of HBLT needed or could low intensity HBLT be an equally effective alternative; and if so, for whom? Our proposed project will answer these important questions that arise daily in the clinical setting and will generate critical new insights to guide decision-making for teens with obesity and the stakeholders who care deeply about them.

Start Date01 Jan 2026

Sponsor / Collaborator

University of Minnesota

100 Clinical Results associated with Semaglutide (Novo Nordisk)

100 Translational Medicine associated with Semaglutide (Novo Nordisk)

100 Patents (Medical) associated with Semaglutide (Novo Nordisk)

298

Literatures (Medical) associated with Semaglutide (Novo Nordisk)

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes

Article

Author: Lübker, Christopher ; Lincoff, A. Michael ; Bøg, Martin ; Lingvay, Ildiko ; McEwan, Phil ; Toliver, Joshua C. ; Yeates, Florian ; Faurby, Mads ; Miller, Ryan ; Foos, Volker

AIMS:

The cardioprotective effects of semaglutide 2.4 mg reported in the SELECT cardiovascular (CV) outcomes trial (ClinicalTrials.gov NCT03574597) provide clinical benefit for subjects with overweight or obesity and established CV disease without type 2 diabetes (T2D). We assessed cost-effectiveness of semaglutide 2.4 mg in this population against the American College of Cardiology/American Heart Association value framework.

MATERIALS AND METHODS:

A cohort-level Markov-state cost-effectiveness model using trial-derived data with outcomes from a healthcare sector perspective measured over a lifetime horizon was developed. Treatment costs were based on US list prices; scenario analyses used literature-reported estimated rebates. Healthcare costs and benefits were discounted at 3.0%. A simulated cohort of 100,000 subjects was aligned to the SELECT trial population baseline characteristics and time-on-treatment. Subjects received either semaglutide 2.4 mg or placebo in addition to standard of care (SoC). Modelled outcomes included clinical events (CV events, progression to T2D, chronic kidney disease [CKD]) and health economic measures, including direct costs and quality-adjusted life years (QALYs).

RESULTS:

Mean semaglutide 2.4 mg treatment duration was 2.79 years. Per 100,000 subjects, treatment avoided 2,791 non-fatal myocardial infarctions, 3,000 coronary revascularizations, 487 non-fatal strokes, and 115 CV deaths over the modeled lifetime horizon. Average per-subject lifetime treatment costs were $47,353; savings arose from avoided T2D ($14,431), CKD ($2,074), and CV events ($1,512). Semaglutide 2.4 mg was associated with increased lifetime costs ($29,767), additional QALYs gained (0.218) and an incremental cost-effectiveness ratio of $136,271/QALY at list price; a scenario using an empirically estimated 48% rebate predicted $32,219/QALY.

LIMITATIONS:

The generalizability of observations from SELECT to a broader US population is unknown. Our model does not capture all outcomes nor costs that may be affected by weight loss. Modeling assumptions may present limitations.

CONCLUSIONS:

Semaglutide 2.4 mg use as in SELECT is cost-effective at list price, using a $150,000/QALY willingness-to-pay threshold.

01 Sep 2025·Obesity Pillars

Antiemetic effect of acupressure wristbands for GLP-1 medication associated nausea

Article

Author: Belarj, Soufiane ; Reyes, Anita ; Ziemke, Florencia ; Istfan, Nawfal ; Esguerra, Jem

Background:

Nausea is one of the most reported side effect of GLP-1 receptor agonists (GLP-1a). Current recommendations fall short in taming the symptoms, include antiemetic medication, behavior changes, GLP-1a dose adjustment, and often cause a disruption to treatment. Sea-Band® is a drug-free, class II FDA-cleared medical device for relief of nausea in motion sickness, morning sickness, chemotherapy and anesthesia induced nausea. The device is a set of soft, elastic, reusable acupressure wristbands (ACW) with a skin-facing plastic button worn below the wrist crease applying pressure at acupoint pericardium 6. We hypothesized that ACW was an effective tool for GLP-1a associated nausea.

Methods:

This was a one-arm, open-label, non-randomized, prospective interventional study evaluating the antiemetic effect of ACW in non-pregnant adults on GLP-1as with nausea. GLP-1a were semaglutide or tirzepatide. Exclusion criteria were patients on GLP-1a without nausea, recent use of antiemetic medications, other nausea-related conditions, history of gastroparesis, and uncontrolled gastroesophageal reflux disease. Patients were shown how to properly place and use ACW at the onset of nausea and were followed weekly for 4 weeks. Follow-ups assessed frequency of nausea, ACW use frequency and duration, and change in nausea.

Results:

359 episodes of nausea were recorded amongst 31 adult participants over 4 weeks. Adults, mean age 55, mean BMI 34, mean HbA1c 5.9 %, reported nausea over 80 % of the time on a weekly basis. ACW were used in all recorded episodes of nausea. Medication doses were kept stable throughout the duration of this study. Nausea relief was achieved within 5 min in one third of episodes, and in over 5 min but under 20 min in the remainder of the episodes. A logistic regression model was used to evaluate the likelihood of nausea relief. A consistent rate of nausea relief over 80 % was observed during the study period, adjusting for the correlation between reduced nausea episodes and reduced episodes.

Conclusion:

Although not a controlled trial, this pilot, proof of concept, pragmatic study suggests that ACW may offer a safe, self-administered, reusable, and drug-free option for managing GLP-1a associated nausea.ACW's nausea reducing effect was seen in over 80 % of episodes, and remained consistent throughout the study period. One third of participants experienced relief within 5 min of wearing ACW in the first three weeks. Given the relatively small sample size of the population, further large-scale investigations are justified. Nausea is common in day-to-day real-world use of GLP-1as, and our results suggest that using ACW may provide a first-line therapeutic intervention used ad libitum to tame a disruptive symptom, improve day-to-day well-being, and positively impact a person's treatment journey on GLP-1a.

01 Jul 2025·JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

TikTok’s Take on Adverse Effects for Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide Receptor Agonists

Article

Author: Wantuch, Gwendolyn A ; Singleton, Jerica

BACKGROUND:

TikTok's MedTok is an interconnected network of patients, providers, and producers sharing knowledge and experiences of health-related topics. Awareness of popular content on weight loss medications can benefit healthcare professionals, especially regarding side effects and management.

OBJECTIVES:

Describe content in popular TikTok videos using side effect hashtags for gastric inhibitory peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. Compare content between healthcare and non-healthcare creators and reported side effects versus medication package inserts.

METHODS:

This observational study evaluated videos for popular GLP-1 and GIP receptor agonist side-effect hashtags on TikTok, in June 2023. Video metadata collected included content creator demographics, and content of video including side effects discussed and recommendations to address these. Side effects were compared to package insert data. Qualitative data was evaluated through descriptive coding, quantitative data through descriptive statistics and Pearson chi-square for comparisons.

RESULTS:

A total of 165 videos were analyzed. Content creators were mostly medication users (89%) and non-healthcare professionals (90%). Medication indications included weight loss (82%), PCOS (20%), and diabetes (6%). Diet, exercise, or weight loss were discussed in 34%, 16%, and 38% of videos, respectively. Non-healthcare professionals mentioned specific products to address side effects more frequently than healthcare professionals, 24% versus 13% (p = 0.292). All side effects mentioned in at least five videos aligned with medication package inserts, most commonly gastrointestinal disturbances, except for insomnia.

CONCLUSION:

Most content creators were non-healthcare professionals and medication users. Despite Ozempic and Mounjaro lacking FDA approval for weight loss at the time, it was the most identified indication. The alignment of most reported side effects with medication package inserts underscores the reliability of user-shared experiences, though discrepancies like insomnia were noted. Given TikTok's significant reach and influence, awareness of patient-reported experiences and recommendations is essential for healthcare providers to enhance care and dispel misconceptions.

2,175

News (Medical) associated with Semaglutide (Novo Nordisk)

25 Jun 2025

·actimedtherapeutics.com

Actimed Therapeutics Enrols First Patients in Phase 2a PROACT Study Programme to Assess S-pindolol benzoate in Obese Patients During and Post-GLP-1 Agonist Therapy

Two-part clinical study programme to evaluate change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst 1) receiving the GLP-1 agonist semaglutide; and 2) after cessation of semaglutide treatment Initial proof-of-concept data expected in second half of 2026 London, UK – 25 June 2025. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on the treatment of cancer cachexia and other muscle wasting disorders, today announces that the first patients have been enrolled in the Company’s Phase 2a muscle optimisation trial PROACT (Preserving, Restoring, and Optimising (lean mass and muscle) with ACTAs) investigating the use of S-pindolol benzoate in combination with GLP-1 receptor agonists in the management of obesity and related complications. PROACT is a two-part clinical study programme designed to investigate the safety and the efficacy of S-pindolol benzoate in obese patients. PROACT has two independent primary objectives; firstly, to evaluate the change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst also receiving the GLP-1 agonist semaglutide; and secondly, to evaluate the change in lean and fat mass in patients receiving S-pindolol benzoate after cessation of semaglutide treatment. The main secondary endpoints will be to evaluate the potential role of S-pindolol benzoate on muscle mass, heart and bone composition. Initial data from this proof-of-concept study are expected in the second half of 2026. Fabio Dorigotti, Actimed Chief Medical Officer, commented: “The role of S-pindolol benzoate, with its unique pro-anabolic and anti-catabolic profile, in improving muscle mass has been demonstrated in previous clinical trials in patients with cancer cachexia. We believe the PROACT study will also confirm the benefit of S-pindolol benzoate in preserving muscle mass when used alongside GLP-1 agonists and in optimising and restoring muscle mass after GLP-1 therapy in obese subjects. Our Phase 2a study is designed and powered to give us early proof of concept in this setting, and we look forward to communicating results from the study later next year." Marija Zdravkovic, MD, PhD, FESC, CEO, University Hospital Medical Center Bezanijska kosa, Belgrade, Serbia, added “I am excited to be part of the PROACT study and to contribute to advancing innovative strategies for obesity care. I am particularly delighted that the study will be performed in Serbia and am optimistic that this trial will yield valuable insights and pave the way for a more comprehensive approach to obesity management." *** About Actimed Therapeutics Actimed Therapeutics is a clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of muscle wasting disorders to transform the care of an underserved and vulnerable patient population. Actimed Therapeutics is a clinical stage specialty pharmaceutical company focused on advancing muscle health in cancer cachexia, obesity and other muscle wasting disorders. Cachexia is a wasting disease that is associated with cancer and other serious chronic illnesses and with significant morbidity and mortality. A significant number of cancer patients suffer from cachexia1 and despite its prevalence and devastating clinical effects, there is no globally approved drug for the treatment or prevention of cancer-related cachexia. In obese patients receiving current GLP-1RAs for weight loss, muscle preservation is a challenge and new approaches are desirable that preserve a healthy body weight composition. Actimed is currently preparing for further clinical studies of its lead product ACM-001.1 (S-pindolol benzoate) which is an anti-catabolic and pro-anabolic transforming agent (ACTA) targeting multiple pathways that drive cachexia and muscle preservation. Previous studies with S-pindolol have generated promising Phase 2a proof of concept data in cancer cachexia patients and Actimed has conducted a pharmacokinetic and pharmacodynamic (PK/PD) study of S-pindolol benzoate to characterise this new form. In addition, early non-clinical data confirm a potential role for ACM-001.1 in preserving muscle mass when used in combination with GLP-1s for weight loss. Actimed also owns the global rights to its second asset, S-oxprenolol (ACM-002), which is being developed by the Company for the muscle wasting seen in amyotrophic lateral sclerosis (ALS) where loss of body mass and muscle wasting may impact survival2. US Orphan Drug Designation has been granted to S-oxprenolol for the treatment of ALS. Actimed has licensed the global rights to develop and commercialise S-oxprenolol for all other indications outside of ALS to US company Faraday Pharmaceuticals. FOR MORE INFORMATION Actimed Therapeutics MEDiSTRAVA Frazer Hall, Erica Hollingsworth Tel: +44 (0)203 928 6900 Email: actimed@medistrava.com 1 Anker M et al., J. Cachexia, Sarcopenia and Muscle; 2019: 10: 22 – 24 2Wolf J et al., PMID 28184974 DOI: 10.1007/s00115-117-0293

Phase 2Orphan Drug

25 Jun 2025

·www.biospace.com

Prescription Drug Sales Will Hit $1.75T By 2030 Thanks to GLP-1s: Evaluate

iStock, Yutthana Gaetgeaw Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be three times larger than what AbbVie’s blockbuster Humira ever achieved. Total prescription drug sales are expected to grow to $1.75 trillion by 2030, at which point GLP-1 therapies will make up 9% of total prescriptions, according to a new report from Evaluate. The weight loss and diabetes mega-blockbusters are expected to grow 20% between 2024 and 2030. “They are in a class of their own,” Evaluate said in the World Preview report , published Tuesday. Eli Lilly’s tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss, is expected to rake in $62 billion a year by 2030, according to Evaluate. That valuation would be three times larger than what AbbVie’s blockbuster Humira—long considered the best-selling drug in the world —achieved. It’s double the 2024 sales of Merck’s Keytruda. The broader category of GLP-1 drugs are “projected to reach hitherto unseen sales peaks,” according to Evaluate. This class of drugs is expected to have five of the top 10 slots on the best-sellers list by 2030 and will be four of the most promising candidates in the pipeline. But Lilly appears to be clearly leading the way. “Lilly’s supremacy in this battle is already apparent,” Evaluate wrote. Mounjaro and Zepbound are expected to be the best- and third-best selling drugs by the end of the decade. Lilly’s main competitor is Novo Nordisk, whose semaglutide is marketed as Wegovy for diabetes and Ozempic for weight loss. Those drugs sit at sixth and fifth, respectively. “First-mover Novo Nordisk lost ground due to its sluggish response to manufacturing shortages of Wegovy (semaglutide), which led to a flood of compounded (pharmacy-mixed) drug,” according to the report. Novo has acknowledged some stumbles, even ousting CEO Lars Fruergaard Jørgensen in May in a surprise move. Evaluate did say that Novo’s pipeline asset CagriSema, which combines semaglutide with an amylin agonist, is the most promising asset in R&D at the moment, with peak sales projections of $80 billion. But the drug has stumbled in the clinic, falling short of expectations and forcing Novo to launch a longer-duration trial to test different dosing. “If it doesn’t improve, CagriSema will only match Zepbound in efficacy, yet is more complex to manufacture,” Evaluate said. The Rest of the Best Immuno-inflammatory drugs will also continue to lead, with AbbVie’s Skyrizi and Sanofi/Regeneron’s Dupixent in the forefront and on track to make over $25 billion each in 2030. Oncology, too, will have a story to tell in 2030, with Johnson & Johnson’s Genmab-partnered blood cancer drug Darzalex meeting Merck’s falling star Keytruda as its patent expires in 2028 . The current best-selling immuno-oncology drug will fall to seventh place by 2030. “Keytruda’s 2028 expiry puts Merck at the top of the most exposed companies to patent-related sales losses over the rest of the decade—and is the only top ten drug with negative growth,” Evaluate wrote. But Merck is hoping to patch some of the holes in its Keytruda losses with a subcutaneous formulation that Evaluate named as one of the most valuable pipeline drugs by net present value. “It’s a shining case study in life-cycle management,” the analysis firm said, and one that the forthcoming GLP-1 combos and formulations may be able to copy as pipeline assets like oral GLP-1 orforglipron and triple-G agonist retatrutide are expected to take the market by storm . Pfizer has taken one of the biggest tumbles on Evaluate’s rankings, falling from the number one slot in the pandemic years to last place in the list of top 10 companies with the most drug sales expected in 2030. Novartis is also expected to be stuck in the bottom half as it lacks a standout blockbuster. Sanofi, on the other hand, is the “most impressive” non-GLP-1 company rising up the list, according to Evaluate. The French pharma is rising thanks to Dupixent, which is expected to grow by 10%.

BiosimilarPatent ExpirationAcquisition

24 Jun 2025

·firstwordpharma.com

ADA25: BrightGene’s GLP-1/GIP agonist shows mettle in mid-stage diabetes, obesity studies

BrightGene Pharmaceutical reported upbeat mid-stage results for its investigational dual GLP-1/GIP agonist BGM0504, demonstrating superior glycaemic control over Novo Nordisk’s GLP-1 agonist semaglutide (Wegovy/Ozempic) in patients with type 2 diabetes and significant weight reduction in obese individuals compared with placebo. The data were presented at the American Diabetes Association (ADA) annual meeting.Diabetes trial shows benefitA Phase II diabetes study involving 67 participants evaluated once-weekly subcutaneous BGM0504 across three dose levels against semaglutide and placebo controls. Primary endpoint analysis at week 12 demonstrated dose-dependent HbA1c reductions of -1.72%, -1.94%, and -2.48% for 5 mg, 10 mg and 15 mg BGM0504 groups, respectively, compared with -1.43% for semaglutide and -0.28% for placebo.Notable improvements were observed on secondary endpoints — two-hour postprandial glucose, fasting glucose, body weight, HbA1c and combined HbA1c/weight target proportions — while HOMA2-B, lipids, and blood pressure showed varied improvements. The most common treatment-related gastrointestinal adverse events (AEs) included diarrhoea, nausea, and abdominal distension; no hypoglycaemia or unexpected AEs were reported.Obesity study echoesIn a separate Phase II obesity trial of 120 Chinese patients, BGM0504 across all three dose levels demonstrated significant placebo-adjusted reductions in waist circumference ranging from -8.0 cm to -12.98 cm and body weight in the range of -10.77% to -19.78%. Significant reductions were also noted with BGM0504 in systolic blood pressure (-11.60 to -13.03 mmHg) and diastolic blood pressure (-5.98 to -7.50 mmHg) versus placebo. Moreover, secondary outcomes further reinforced BGM0504’s efficacy, with all doses well tolerated. “These Phase II data highlight the significant, best-in-class potential of BGM0504 as a treatment for type 2 diabetes and obesity,” remarked Jiandong Yuan, chief executive of BrightGene.The results are likely to bring some optimism as BrightGene readies to challenge Eli Lilly’s GLP-1/GIP dual agonist tirzepatide (Mounjaro/Zepbound) in an ongoing head-to-head Phase II obesity trial in China. The company also noted BGM0504 has progressed to late-stage testing in China for weight management and type 2 diabetes, while Phase I bridging studies have concluded in the US.

Phase 2Clinical ResultPhase 1

100 Deals associated with Semaglutide (Novo Nordisk)

External Link

KEGG	Wiki	ATC	Drug Bank
D10025	Semaglutide (Novo Nordisk)	A10BJ06	DB13928

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Chronic Kidney Diseases	United States	Novo Nordisk A/S	28 Jan 2025
Chronic Kidney Diseases	United States	Novo Nordisk, Inc.	28 Jan 2025
Stroke	Australia	Novo Nordisk Pharmaceuticals Pty Ltd.	16 Dec 2024
Myocardial Infarction	Canada	Novo Nordisk Canada, Inc.	27 Nov 2024
Obesity	United States	Novo Nordisk, Inc.	04 Jun 2021
Overweight	United States	Novo Nordisk, Inc.	04 Jun 2021
Diabetes Mellitus, Type 2	United States	Novo Nordisk, Inc.	05 Dec 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Nonalcoholic Steatohepatitis	NDA/BLA	United States	Novo Nordisk A/S	30 Apr 2025
Albuminuria	Phase 3	Canada	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Germany	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Netherlands	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Spain	Novo Nordisk A/S	14 Mar 2022
Osteoarthritis, Knee	Phase 3	United States	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Canada	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Colombia	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Denmark	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	France	Novo Nordisk A/S	01 Oct 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03574597 (SELECT, Pubmed \| J Med Econ)	Phase 3	Cardiovascular Diseases \| Obesity	-	Semaglutide 2.4 mg	vstaoulbop(wwajkirtpm) = jmdjvetkwt kutbigttxc (umziycwhzq ) View more	Positive	31 Dec 2025
NEWS Manual	Not Applicable	Obesity	-	Semaglutide/Tirzepatide	cfarelxiot(qahnrhgyfg) = zijtjwneaq xazqpbfudf (pryawfswkz ) View more	-	10 Jun 2025
NCT04822181 (Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis, Pubmed \| N Engl J Med)	Phase 3	Nonalcoholic Steatohepatitis	1,197	Semaglutide 2.4 mg	zdsmicgycj(qilishfuks) = bkhezyzqzi nhmdtdmowx (mwrpfmdbhz, 7.5 - 21.3) View more	Positive	05 Jun 2025
				Placebo	zdsmicgycj(qilishfuks) = gzoiqtkvil nhmdtdmowx (mwrpfmdbhz ) View more
NCT03914326 (SOUL, Pubmed \| N Engl J Med \| NEWS) Manual	Phase 3	Diabetes Mellitus, Type 2	9,650	Oral Semaglutide	fwrntsdnvk(tvuasgyxit) = wrnlkrnomb bwvxyvuvbe (bymbyxazhg ) View more	Positive	29 May 2025
				Placebo	fwrntsdnvk(tvuasgyxit) = revskhlafg bwvxyvuvbe (bymbyxazhg ) View more
NCT04822181 (ESSENCE, NEWS) Manual	Phase 3	Nonalcoholic Steatohepatitis	-	司美格鲁肽（Wegovy）2.4 mg	fojsqjauya(ahrfulgzzj) = psdjffxwlz yoviusyaiq (vhjsifpsen ) View more	Positive	21 May 2025
				Placebo	fojsqjauya(ahrfulgzzj) = uyhnfxxdcl yoviusyaiq (vhjsifpsen ) View more
ATS2025	Not Applicable	Idiopathic Pulmonary Fibrosis	-	GLP-1 agonists	myvbbsnosn(recboojyvh): HR = 0.62 (95% CI, 0.53 - 0.74), P-Value = <0.01	Positive	16 May 2025
				Glucagon-Like Peptide-1 Agonists (No GLP-1 agonists)
NCT03574597 (SELECT, PRNewswire) Manual	Phase 3	Cardiovascular Diseases	17,604	Wegovy® 2.4 mg	epmoqtutot(csyvqvhdfe): HR = 0.63 (95% CI, 0.41 - 0.95) View more	Positive	13 May 2025
				Placebo
NEWS Manual	Not Applicable	Obesity	-	司美格鲁肽 (2.4mg)	eqbhvxjead(ceakxptnfx) = ezztjtelmy icrumalaym (fgkfrsgafd ) View more	Positive	07 May 2025
NCT05786521 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Insulin Resistance \| Prediabetic State ... View more	20	Semaglutide Injectable Product+Lifestyle Counseling (Semaglutide and Lifestyle Intervention)	wurazsthqk(oorcygwmul) = zywestuqlo yekithmasy (casfzmfkfm, lqjnmcvgoq - sqmdlssxcs) View more	-	04 May 2025
				Lifestyle Counseling (Lifestyle Intervention)	wurazsthqk(oorcygwmul) = iotjqozano yekithmasy (casfzmfkfm, rnivbudnam - vgyawdddhy) View more
NCT04822181 (ESSENCE, PRNewswire \| Pubmed) Manual	Phase 3	Nonalcoholic Steatohepatitis	800	SemaglutideSemaglutide 2.4 mg	eyydwuzqew(sxnbxqjrxc) = rcvapyeulq sxqrrlzaeh (tndbancvyx ) View more	Positive	30 Apr 2025
				Placebo	eyydwuzqew(sxnbxqjrxc) = epzgshfbvs sxqrrlzaeh (tndbancvyx ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis